Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.

– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data ...

Emerging evidence suggests that Cdc13-Stn1-Ten1 (CST), an RPA-like ssDNA-binding complex, may regulate primase-Pol α (PP) activity at telomeres constitutively, and at other genomic locations under ...

Replication of DNA requires helicase and primase activities as part of a primosome assembly. In bacteriophage T4, helicase and primase are separate polypeptides for which little structural information ...

The cellular replicative DNA polymerases cannot initiate DNA synthesis without a priming 3′ OH. During DNA replication, this is supplied in the context of a short RNA primer molecule synthesized by ...

March 21, 2012 (San Diego, California) — A novel helicase-primase inhibitor with antiviral activity against the varicella zoster virus might provide an alternative as potent as current treatments for ...

The herpes simplex virus (HSV) causes cold sores and genital lesions and with the exception of acyclovir (an inhibitor of the viral DNA polymerase), there are currently no drug treatments available.

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.

Primases are essential components of the DNA replication apparatus in every organism. They catalyze the synthesis of oligoribonucleotides on single-stranded DNA, which subsequently serve as primers ...